Comparison between gleason score and apparent diffusion coefficient obtained from diffusion-weighted imaging of prostate cancer patients

Cancer Investigation

Volumn 31, Issue 9, 2013, Pages 625-629

  Caivano, Rocchina ^a   Rabasco, Paola ^a   Lotumolo, Antonella ^a   Cirillo, Patrizia ^a   D'Antuono, Felice ^a   Zandolino, Alexis ^a   Villonio, Antonio ^a   Macarini, Luca ^b   Salvatore, Marco ^a,c   Cammarota, Aldo ^a  

^a REFERRAL CANCER CENTER OF BASILICATA   (Italy)

^b UNIVERSITY OF FOGGIA   (Italy)

^c IRCCS SDN   (Italy)

Author keywords

ADC; Diffusion weighted imaging; Gleason score; Magnetic resonance imaging; Prostate cancer

Indexed keywords

ADULT; AGED; ARTICLE; CANCER STAGING; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIFFUSION COEFFICIENT; DIFFUSION WEIGHTED IMAGING; GLEASON SCORE; HUMAN; HUMAN TISSUE; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROSTATE CARCINOMA; TRANSRECTAL ULTRASONOGRAPHY;

AGED; AGED, 80 AND OVER; BIOPSY; DIFFUSION MAGNETIC RESONANCE IMAGING; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES;

EID: 84887231187     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.3109/07357907.2013.845673     Document Type: Article

References (30)

1. Kundra V, Silverman PM, Matin SF, Choi H. Imaging in oncology from the University of Texas M. D. Anderson Cancer Center: diagnosis, staging, and surveillance of prostate cancer. Am J Roentgenol 2007;189:830-844.
2. Boscaino A, Di Costanzo G, Giovagnoni A, Maggioni F, Ragozzino A, Regine R, et al. Carcinoma della prostata. Risonanza magnetica: l'essenziale.
3. Schr̈oder FH, Jonas Hugosson J, Roobol MJ, et al. Prostatecancer mortality at 11 years of follow-up. N Engl J Med 2012;366:981-990.
4. Kelloff GJ, Choyke P, Coffey DS. Challenges in clinical prostate cancer: role of imaging. Am J Roentgenol 2009;192:1455-1470.
5. Lawrentschuk N, Fleshner N. The role of magnetic resonance imaging in targeting prostate cancer in patients with previous negative biopsies and elevated prostate-specific antigen levels. BJU Int 2009;103:730-733.
6. Kurhanewicz J, Vigneron D, Carroll P, Coakley F. Multiparametric magnetic resonance imaging in prostate cancer: present and future. Curr Opin Urol 2008;18:71-77.
7. Engelbrecht MR, Jager GJ, Laheij RJ, Verbeek AL, van Lier HJ, Barentsz JO. Local staging of prostate cancer using magnetic resonance imaging: a meta-analysis. Eur Radiol 2002;12:2294-2302.
8. Caivano R, Cirillo P, Balestra A, Lotumolo A, Fortunato G, Macarini L, et al. Prostate cancer in magnetic resonance imaging: diagnostic utilities of spectroscopic sequences. JMed Imag Radiat Oncol 2012;56(6):606-616.
9. Yamamura J, Salomon G, Buchert R, Hohenstein A, Graessner J, Huland H, et al. MR imaging of prostate cancer: diffusion weighted imaging and (3D) hydrogen 1 (1H)MR spectroscopy in comparison with histology radiology research and practice volume. Radiol Res Pract 2011;2011:616852.
10. Nagarajan R, Margolis D, Raman S, Sheng K, King C, Reiter R, et al. Correlation of Gleason scores with diffusion-weighted imaging findings of prostate cancer. Adv Urol 2012;2012:374805.
11. Kagebayashi Y, Nakai Y, Matsumoto Y, Samma S, Miyasaka T, Nakagawa H. Utility of diffusion-weighted magnetic resonance imaging and apparent diffusion coefficient in detection of prostate cancer and prediction of pathologic Gleason score. Hinyokika Kiyo 2012;58:405-408.
12. Doo KW, Sung DJ, Park BJ, Kim MJ, Cho SB, Oh YW, et al. Detectability of low and intermediate or high risk prostate cancer with combined T2-weighted and diffusion-weighted MRI. Eur Radiol 2012;22:1812-1819.
13. Ibrahiem EI, Mohsen T, Nabeeh AM, Osman Y, Hekal IA, Abou El-GharM. DWI-MRI: single, informative, and noninvasive technique for prostate cancer diagnosis. SciWorld J 2012;2012:973450.
14. Somford DM, Hambrock T, Hulsbergen-van de Kaa CA, F̈utterer JJ, van Oort IM, van Basten JP, Karthaus HF, Witjes JA, Barentsz JO. Initial experience with identifying high-grade prostate cancer using diffusion-weighted MR imaging (DWI) in patients with a Gleason score ?3 + 3 = 6 upon schematic TRUS-guided biopsy: a radical prostatectomy correlated series. Invest Radiol 2012;47:153-158.
15. Cornud F, Delongchamps NB, Mozer P, Beuvon F, Schull A, Muradyan N, Peyromaure M. Value of multiparametric MRI in the work-up of prostate cancer. Curr Urol Rep 2012;13:82-92.
16. Oto A, Yang C, Kayhan A, Tretiakova M, Antic T, Schmid-Tannwald C, Eggener S, Karczmar GS, Stadler WM. Diffusionweighted and dynamic contrast-enhancedMRI of prostate cancer: correlation of quantitativeMR parameters with Gleason score and tumor angiogenesis. Am J Roentgenol 2011;197:1382-1390.
17. Woodfield CA, Tung GA, Grand DJ, Pezzullo JA, Machan JT, Renzulli JF 2nd. Diffusion-weighted MRI of peripheral zone prostate cancer: comparison of tumor apparent diffusion coefficient with Gleason score and percentage of tumor on core biopsy. Am J Roentgenol 2010;194:316-322.
18. Hambrock T, Hoeks C, Hulsbergen-van de Kaa C, Scheenen T, F̈utterer J, Bouwense S, van Oort I, Schr̈oder F, Huisman H, Barentsz J. Prospective assessment of prostate cancer aggressiveness using 3-T diffusion-weighted magnetic resonance imaging-guided biopsies versus a systematic 10-core transrectal ultrasound prostate biopsy cohort. Eur Urol 2012;61:177-184.
19. Pickles MD, Gibbs P, Sreenivas M, Turnbull LW. Diffusionweighted imaging of normal and malignant prostate tissue at 3. 0T. J Magn Reson Imaging 2006;23:130-134.
20. Hambrock T, Somford DM, Huisman HJ, van Oort IM,Witjes JA, Hulsbergen-van de Kaa CA, Scheenen T, Barentsz JO. Relationship between apparent diffusion coefficients at 3. 0-T MR imaging and Gleason grade in peripheral zone prostate cancer. Radiology 2011;259(2):453-461.
21. Tamada T, Sone T, Jo Y, Toshimitsu S, Yamashita T, Yamamoto A, Tanimoto D, et al. Apparent diffusion coefficient values in peripheral and transition zones of prostate: comparison between normal and malignant prostatic tissues and correlation with histologic grade. J Magn Res Imag 2008;28:720-726.
22. Haider MA, van der Kwast TH, Tanguay J, Evans AJ, Hashmi AT, Lockwood G, et al. Combined T2-weighted and diffusionweighted MRI for localization of prostate cancer. AmJ Roentgenol 2007;189:323-328.
23. Mullerad M, Hricak H, Kuroiwa K, Pucar D, Chen HN, Kattan MW, et al. Comparison of endorectal magnetic resonance imaging, guided prostate biopsy and digital rectal examination in the preoperative anatomical localization of prostate cancer. J Urol 2005;174:2158-2163.
24. KimJK, Jang YJ, Cho G. Multidisciplinary functionalMR Imaging for Prostate Cancer. Korean J Radiol 2009;10:535-551.
25. KimCK, Park BK, Kim B. High b-Value Diffusion-weighted imaging at 3T to detect prostate cancer: Comparisons between b value of 1000 and 2000 s/mn2. Am J Roentgenol 2010;194:33-37.
26. Kitajima K, Kaji Y, Kuroda K, Sugimura K. High b-value diffusion-weighted imaging in normal and malignant peripheral zone tissue of the prostate: effect of signal-to-noise ratio. Magn Reson Med Sci 2008;7:93-99.
27. Bentzen S. Theragnostic imaging for radiation oncology: dosepainting by numbers. Lancet Oncol 2005;6:112-117.
28. Pedicini P, Strigari L, BenassiM. Estimation of a self-consistent set of radiobiological parameters from hypofractionated versus standard radiation therapy of prostate cancer. Int J Radiat Oncol Biol Phys 2013;85(5):231-237.
29. Pedicini P, Caivano R, Strigari L, Benassi M, Fiorentino A, Fusco V. In regard to Miralbell et al. Re: Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5969 patients in seven international institutional datasets: alpha/beta = 1. 4 (0. 9-2. 2) Gy. Int J Radiat Oncol Biol Phys 2013;85(1):10-11.
30. Pedicini P. Kick-off time for accelerated cell repopulation during the radiotherapy: the hypothesis of stem-cells. Int J Radiat Oncol Biol Phys 2013. DOI: 10. 1016/j. ijrobp. 2013. 08. 016.